Review: Serum and urine biomarkers of kidney disease: A pathophysiological perspective

Nephrology

Volumn 15, Issue 6, 2010, Pages 609-616

  Tesch, Greg H ^a,b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

biomarker; kidney disease; renal function; renal injury; serum; urine

Indexed keywords

BIOLOGICAL MARKER;

BLOOD ANALYSIS; BLOOD LEVEL; CHROMATOGRAPHY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; MASS SPECTROMETRY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK FACTOR; URINALYSIS; URINE LEVEL;

ANIMALS; BIOLOGICAL MARKERS; FIBROSIS; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 77956221158     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01361.x     Document Type: Review

References (82)

1. Srisawat N, Hoste EE, Kellum JA. Modern classification of acute kidney injury. Blood Purif. 2010 29 : 300 307.
2. NKF. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002 39 : S1 266.
3. Waikar SS, Bonventre JV. Can we rely on blood urea nitrogen as a biomarker to determine when to initiate dialysis? Clin. J. Am. Soc. Nephrol. 2006 1 : 903 904.
4. Schwartz GJ, Kwong T, Erway B et al. Validation of creatinine assays utilizing HPLC and IDMS traceable standards in sera of children. Pediatr. Nephrol. 2009 24 : 113 119.
5. Rule AD. Understanding estimated glomerular filtration rate: Implications for identifying chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2007 16 : 242 249.
6. Curhan G. Cystatin C: A marker of renal function or something more? Clin. Chem. 2005 51 : 293 294.
7. Mussap M, Dalla Vestra M, Fioretto P et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int. 2002 61 : 1453 1461.
8. Herget-Rosenthal S, Marggraf G, Husing J et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004 66 : 1115 1122.
9. Feig DI. Uric acid: A novel mediator and marker of risk in chronic kidney disease? Curr. Opin. Nephrol. Hypertens. 2009 18 : 526 530.
10. Urushihara M, Kondo S, Kagami S, Kobori H. Urinary Angiotensinogen Accurately Reflects Intrarenal Renin-Angiotensin System Activity. Am. J. Nephrol. 2010 31 : 318 325.
11. Deekajorndech T. A biomarker for detecting early tubulointerstitial disease and ischemia in glomerulonephropathy. Ren. Fail. 2007 29 : 1013 1017.
12. DeRubertis FR, Craven PA, Melhem MF. Acceleration of diabetic renal injury in the superoxide dismutase knockout mouse: Effects of tempol. Metabolism 2007 56 : 1256 1264.
13. Oberg BP, McMenamin E, Lucas FL et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004 65 : 1009 1016.
14. Dincer Y, Sekercioglu N, Pekpak M, Gunes KN, Akcay T. Assessment of DNA oxidation and antioxidant activity in hypertensive patients with chronic kidney disease. Ren. Fail. 2008 30 : 1006 1011.
15. Dounousi E, Papavasiliou E, Makedou A et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am. J. Kidney. Dis. 2006 48 : 752 760.
16. Nakamura N, Kumasaka R, Osawa H et al. Effects of eicosapentaenoic acids on oxidative stress and plasma fatty acid composition in patients with lupus nephritis. In Vivo 2005 19 : 879 882.
17. Calabrese V, Mancuso C, Sapienza M et al. Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaperones 2007 12 : 299 306.
18. Radabaugh MR, Nemirovskiy OV, Misko TP, Aggarwal P, Mathews WR. Immunoaffinity liquid chromatography-tandem mass spectrometry detection of nitrotyrosine in biological fluids: Development of a clinically translatable biomarker. Anal. Biochem. 2008 380 : 68 76.
19. Furuya R, Kumagai H, Odamaki M, Takahashi M, Miyaki A, Hishida A. Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients. Nephron Clin. Pract. 2009 112 : c255 61.
20. Slowik-Zylka D, Safranow K, Dziedziejko V, Ciechanowski K, Chlubek D. Association of plasma pentosidine concentrations with renal function in kidney graft recipients. Clin. Transplant. 2009 doi: 10.1111/j.1399-0012.2009.01177.x [epub ahead of print[.
21. Polkinghorne KR. Detection and measurement of urinary protein. Curr. Opin. Nephrol. Hypertens. 2006 15 : 625 630.
22. Comper WD, Osicka TM, Clark M, MacIsaac RJ, Jerums G. Earlier detection of microalbuminuria in diabetic patients using a new urinary albumin assay. Kidney Int. 2004 65 : 1850 1855.
23. Magliano DJ, Polkinghorne KR, Barr EL et al. HPLC-detected albuminuria predicts mortality. J. Am. Soc. Nephrol. 2007 18 : 3171 3176.
24. Wang G, Lai FM, Lai KB, Chow KM, Li KT, Szeto CC. Messenger RNA expression of podocyte-associated molecules in the urinary sediment of patients with diabetic nephropathy. Nephron Clin. Pract. 2007 106 : c169 79.
25. Wang G, Lai FM, Tam LS et al. Messenger RNA expression of podocyte-associated molecules in urinary sediment of patients with lupus nephritis. J. Rheumatol. 2007 34 : 2358 2364.
26. Kanno K, Kawachi H, Uchida Y, Hara M, Shimizu F, Uchiyama M. Urinary sediment podocalyxin in children with glomerular diseases. Nephron Clin. Pract. 2003 95 : c91 9.
27. Bazzi C, Petrini C, Rizza V et al. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol. Dial. Transplant. 2002 17 : 1890 1896.
28. Han WK, Waikar SS, Johnson A et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int. 2008 73 : 863 869.
29. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J. Pathol. 2007 212 : 209 217.
30. Vaidya VS, Ford GM, Waikar SS et al. A rapid urine test for early detection of kidney injury. Kidney Int. 2009 76 : 108 114.
31. Portilla D, Dent C, Sugaya T et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2008 73 : 465 472.
32. Kamijo A, Sugaya T, Hikawa A et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial. J. Lab. Clin. Med. 2005 145 : 125 133.
33. Tanaka T, Doi K, Maeda-Mamiya R et al. Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury. Am. J. Pathol. 2009 174 : 1203 1211.
34. Mishra J, Ma Q, Prada A et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 2003 14 : 2534 2543.
35. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int. 2007 71 : 967 970.
36. Pickering JW, Endre ZH. Secondary prevention of acute kidney injury. Curr. Opin. Crit. Care 2009 15 : 488 497.
37. Bolignano D, Lacquaniti A, Coppolino G et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009 4 : 337 344.
38. Zhou H, Cheruvanky A, Hu X et al. Urinary exosomal transcription factors, a new class of biomarkers for renal disease. Kidney Int. 2008 74 : 613 621.
39. Bazzi C, Petrini C, Rizza V et al. Fractional excretion of IgG predicts renal outcome and response to therapy in primary focal segmental glomerulosclerosis: A pilot study. Am. J. Kidney Dis. 2003 41 : 328 335.
40. Tan Y, Zhang JJ, Liu G, Zhang H, Zhao MH. The level of urinary secretory immunoglobulin A (sIgA) of patients with IgA nephropathy is elevated and associated with pathological phenotypes. Clin. Exp. Immunol. 2009 156 : 111 116.
41. Bakoush O, Segelmark M, Torffvit O, Ohlsson S, Tencer J. Urine IgM excretion predicts outcome in ANCA-associated renal vasculitis. Nephrol. Dial. Transplant. 2006 21 : 1263 1269.
42. Bakoush O, Torffvit O, Rippe B, Tencer J. Renal function in proteinuric glomerular diseases correlates to the changes in urine IgM excretion but not to the changes in the degree of albuminuria. Clin. Nephrol. 2003 59 : 345 352.
43. Branten AJ, Kock-Jansen M, Klasen IS, Wetzels JF. Urinary excretion of complement C3d in patients with renal diseases. Eur. J. Clin. Invest. 2003 33 : 449 456.
44. Manzi S, Rairie JE, Carpenter AB et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 1996 39 : 1178 1188.
45. Zhang JJ, Jiang L, Liu G et al. Levels of urinary complement factor H in patients with IgA nephropathy are closely associated with disease activity. Scand. J. Immunol. 2009 69 : 457 464.
46. Endo M, Fuke Y, Tamano M et al. Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy. Nephron Clin. Pract. 2004 97 : c147 53.
47. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006 69 : 73 80.
48. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol. 2005 16 : 467 473.
49. Wada T, Furuichi K, Sakai N et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 2000 58 : 1492 1499.
50. Niewczas MA, Ficociello LH, Johnson AC et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin. J. Am. Soc. Nephrol. 2009 4 : 62 70.
51. Hu H, Aizenstein BD, Puchalski A, Burmania JA, Hamawy MM, Knechtle SJ. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am. J. Transplant. 2004 4 : 432 437.
52. Matz M, Beyer J, Wunsch D et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int. 2006 69 : 1683 1690.
53. Wu T, Xie C, Wang HW et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J. Immunol. 2007 179 : 7166 7175.
54. Schramme A, Abdel-Bakky MS, Gutwein P et al. Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. Kidney Int. 2008 74 : 328 338.
55. Brown FG, Nikolic-Paterson DJ, Hill PA et al. Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J. Am. Soc. Nephrol. 2002 13 (Suppl 1 S7 13.
56. Brown FG, Nikolic-Paterson DJ, Chadban SJ et al. Urine macrophage migration inhibitory factor concentrations as a diagnostic tool in human renal allograft rejection. Transplantation 2001 71 : 1777 1783.
57. Tesar V, Masek Z, Rychlik I et al. Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol. Dial. Transplant. 1998 13 : 1662 1667.
58. Lederer SR, Friedrich N, Regenbogen C, Getto R, Toepfer M, Sitter T. Non-invasive monitoring of renal transplant recipients: Urinary excretion of soluble adhesion molecules and of the complement-split product C4d. Nephron Clin. Pract. 2003 94 : c19 26.
59. Parikh CR, Jani A, Mishra J et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am. J. Transplant. 2006 6 : 1639 1645.
60. Kilis-Pstrusinska K, Medynska A, Zwolinska D, Wawro A. Interleukin-18 in urine and serum of children with idiopathic nephrotic syndrome. Kidney Blood Press. Res. 2008 31 : 122 126.
61. Iglesias J, Marik PE, Levine JS. Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock. Am. J. Kidney. Dis. 2003 41 : 62 75.
62. Ting YT, Coates PT, Marti HP et al. Urinary soluble HLA-DR is a potential biomarker for acute renal transplant rejection. Transplantation 2010 89 : 1071 1078.
63. Tsakas S, Goumenos DS. Accurate measurement and clinical significance of urinary transforming growth factor-beta1. Am. J. Nephrol. 2006 26 : 186 193.
64. Cheng O, Thuillier R, Sampson E et al. Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am. J. Transplant. 2006 6 : 2292 2306.
65. Gilbert RE, Akdeniz A, Weitz S et al. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 2003 26 : 2632 2636.
66. Cha DR, Kim IS, Kang YS et al. Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus. Diabet. Med. 2005 22 : 14 20.
67. Torii K, Kimura H, Li X et al. [Diabetic nephropathy and plasminogen activator inhibitor 1 in urine samples]. Rinsho Byori 2004 52 : 506 512.
68. Bobkova IN, Kozlovskaia LV, Rameeva AS, Varshavskii VA, Golitsyna EP. [Clinical implication of urine test for markers of endothelial dysfunction and angiogenesis factors in assessment of tubulointerstitial fibrosis in chronic glomerulonephritis]. Ter. Arkh. 2007 79 : 10 15.
69. Io H, Hamada C, Fukui M, Horikoshi S, Tomino Y. Relationship between levels of urinary type IV collagen and renal injuries in patients with IgA nephropathy. J. Clin. Lab. Anal. 2004 18 : 14 18.
70. Cohen MP, Lautenslager GT, Shearman CW. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice. Metabolism 2001 50 : 1435 1440.
71. Cohen MP, Lautenslager GT, Shearman CW. Increased collagen IV excretion in diabetes. A marker of compromised filtration function. Diabetes Care 2001 24 : 914 918.
72. Cohen MP, Shearman CW, Lautenslager GT. Serum type IV collagen in diabetic patients at risk for nephropathy. Diabetes Care 2001 24 : 1324 1327.
73. Kiani AN, Johnson K, Chen C et al. Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. J. Rheumatol. 2009 36 : 2224 2230.
74. Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel GA. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J. Gerontol. A Biol. Sci. Med. Sci. 2008 63 : 879 884.
75. Zhou H, Pisitkun T, Aponte A et al. Exosomal Fetuin-A identified by proteomics: A novel urinary biomarker for detecting acute kidney injury. Kidney Int. 2006 70 : 1847 1857.
76. Schaub S, Wilkins JA, Antonovici M et al. Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am. J. Transplant. 2005 5 : 729 738.
77. Dihazi H, Muller GA, Lindner S et al. Characterization of diabetic nephropathy by urinary proteomic analysis: Identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin. Chem. 2007 53 : 1636 1645.
78. Haubitz M, Wittke S, Weissinger EM et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005 67 : 2313 2320.
79. Mosley K, Tam FW, Edwards RJ, Crozier J, Pusey CD, Lightstone L. Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology (Oxford) 2006 45 : 1497 1504.
80. Otu HH, Can H, Spentzos D et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007 30 : 638 643.
81. Rossing K, Mischak H, Dakna M et al. Urinary proteomics in diabetes and CKD. J. Am. Soc. Nephrol. 2008 19 : 1283 1290.
82. Knepper MA. Common sense approaches to urinary biomarker study design. J. Am. Soc. Nephrol. 2009 20 : 1175 1178.